Investigation summary: sample evaluation: one open 1ml packaged syringe with needle was received by bd (b)(4) and confirmed to be from batch #7215560 (p/n 309626).The sample was visually evaluated.The syringe was found to have liquid drops in the fluid path.The liquid drops appear to be reddish in tint.The sample was sent for ftir evaluation to flks.The sample was examined and exhibited dark liquid droplets on the surface of the barrel tip and on the inner surface of the hub.A few minutes after removing the needle from the barrel, the dark liquid droplets crystallized and formed solid material.As per request, a small portion of this material was removed from the sample and prepared for ftir spectral analysis.The spectral analysis shows that the material is most likely a type of medication (carboxymethylcellulose sodium salt and a glycol derivative shown for comparison).Based on the sample evaluation, the fluid observed cannot be confirmed to have originated during the manufacturing process.It appears that the sample had been manipulated prior to its return for evaluation.Dhr review for batch 7215560 (p/n 309626): manufacturing date: 08/04/2017 to 08/05/2017.Batch quantity was (b)(4).All visual inspections were performed as per requirement with no quality notifications related to the complaint defect.Batch 7215560 was inspected and accepted based on meeting our inspection control plan and subsequently approved for shipment.Investigation conclusion: root cause and capa not required as not defects were confirmed.
|